-
公开(公告)号：US20240050460A1
公开(公告)日：2024-02-15
申请号：US18152249
申请日：2023-01-10
Applicant: StemRIM Inc. , Osaka University
Inventor： Katsuto TAMAI , Takehiko YAMAZAKI , Yasufumi KANEDA
IPC: A61K31/711 , G01N33/68 , C07K14/52 , G01N33/50
CPC classification number: A61K31/711 , G01N33/6863 , C07K14/52 , G01N33/5073 , A61K38/00
Abstract: The present inventors revealed the following for the first time in the world:
1) a large amount of bone marrow-derived cells are mobilized to grafted skin;
2) the mobilized bone marrow-derived cells are differentiated into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in the grafted skin, and the mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells;
3) the factors which mobilize bone marrow-derived mesenchymal stem cells from peripheral blood to the grafted skin are HMGB1, HMGB2, and HMGB3 released from the necrosed tissue of recipient skin;
4) purified HMGB1, HMGB2, and HMGB3 promote the migration of mesenchymal stem cells isolated and cultured from bone marrow;
5) activators containing HMGB1 which allows the migration of bone marrow mesenchymal stem cells can be conveniently purified from several organ extracts including skin, brain, and heart;
6) activators which allow the migration of bone marrow mesenchymal stem cells can be conveniently extracted from cultured cells; and
7) a heparin-column purified fraction of skin extract mobilizes a large amount of bone marrow-derived cells in case of brain injury.-
公开(公告)号：US20230241159A1
公开(公告)日：2023-08-03
申请号：US17995017
申请日：2021-04-02
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto TAMAI , Takashi SHIMBO , Takehiko YAMAZAKI
CPC classification number: A61K38/16 , A61P9/10 , A61P17/00 , A61P29/00 , C07K14/001
Abstract: The present inventors synthesized a plurality of peptides each consisting of a partial sequence of the artificial sequence peptide “1r10” (1r10 fragment peptides), which was discovered from their own research conducted to date, investigated whether they have an activity of mobilizing mesenchymal stem cells into peripheral blood, and as a result, discovered that a 1r10 fragment peptide having a specific amino acid sequence shows the activity. Based on such finding, a peptide is provided which is considered to show therapeutic effects on various diseases through mobilization of mesenchymal stem cells into peripheral blood.
-
公开(公告)号：US20240050481A1
公开(公告)日：2024-02-15
申请号：US18017149
申请日：2021-07-21
Applicant: OSAKA UNIVERSITY , STEMRIM INC.
Inventor： Katsuto TAMAI , Yasushi KIKUCHI , Tomoki TAMAKOSHI , Takehiko YAMAZAKI
IPC: A61K35/28 , C12N5/0775 , C07K14/78 , A61P17/00
CPC classification number: A61K35/28 , C12N5/0668 , C07K14/78 , A61P17/00
Abstract: The present disclosure includes a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a blister-derived cell of a patient with dystrophic epidermolysis bullosa that is genetically modified to produce type VII collagen.
-
公开(公告)号：US20200291359A1
公开(公告)日：2020-09-17
申请号：US16768203
申请日：2018-11-30
Applicant: STEMRIM INC. , OSAKA UNIVERSITY
Inventor： Katsuto TAMAI , Takashi SHIMBO , Eiji SASAKI , Takehiko YAMAZAKI
IPC: C12N5/0775 , A61K35/28 , G01N33/50 , C07K14/47
Abstract: The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index.
-
公开(公告)号：US20220009976A1
公开(公告)日：2022-01-13
申请号：US17281862
申请日：2019-10-04
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto TAMAI , Takashi SHIMBO , Takehiko YAMAZAKI , Koichi YOKOTA
Abstract: The present inventors designed an artificial sequence peptide based on the results of original research conducted so far, and found that the peptide exhibits an activity of mobilizing mesenchymal stem cells into peripheral blood. The present inventors also found that the artificial sequence peptide has a therapeutic effect on inflammatory bowel disease, atopic dermatitis, and cerebral infarction. Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.
-
Patent Agency Ranking
公开(公告)号：US20210386823A1
公开(公告)日：2021-12-16
申请号：US17287636
申请日：2019-10-25
Applicant: OSAKA UNIVERSITY , STEMRIM INC.
Inventor： Katsuto TAMAI , Takashi SHIMBO , Eiji SASAKI , Takahiro TSUSHIMA , Takehiko YAMAZAKI
Abstract: The inventors of the present invention searched for a substance that is effective in treating a cartilage disorder, and as a result, found that, in an animal model of joint cartilage deficiency, an HMGB1 fragment peptide having a specific amino acid sequence exhibits the effect of reproducing a healthy cartilage tissue including a hyaline cartilage. Based on this finding, the present invention provides a pharmaceutical composition that contains the specific HMGB1 fragment peptide and that is for preventing and/or treating a cartilage disorder.
-
公开(公告)号：US20210347839A1
公开(公告)日：2021-11-11
申请号：US17282872
申请日：2019-10-04
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto TAMAI , Takashi SHIMBO , Takehiko YAMAZAKI
Abstract: The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.
-
公开(公告)号：US20200038486A1
公开(公告)日：2020-02-06
申请号：US16499604
申请日：2018-04-06
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto TAMAI , Takahiro AOTO , Sho YAMAZAKI , Takehiko YAMAZAKI
Abstract: The present inventors discovered that an HMGB1 fragment peptide having a particular amino acid sequence exhibits effects of inhibiting finger adhesion and digestive tract scarring and prolonging survival in the dystrophic epidermolysis bullosa model mice. Also in the skin ulcer model, administration of the specific HMGB1 fragment peptide was found to inhibit the fibrosing of skin during the healing process of the ulcer. Based on these findings, the present application provides pharmaceutical compositions for the treatment of fibrotic diseases, which comprise the specific HMGB1 fragment peptide.
-
公开(公告)号：US20240368235A1
公开(公告)日：2024-11-07
申请号：US18776908
申请日：2024-07-18
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto TAMAI , Takashi SHIMBO , Takehiko YAMAZAKI
Abstract: The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.
-
公开(公告)号：US20240299496A1
公开(公告)日：2024-09-12
申请号：US18697330
申请日：2022-09-30
Applicant: Osaka University , Niigata University , StemRIM Inc.
Inventor： Katsuto TAMAI , Takashi SHIMBO , Shuji TERAI , Atsunori TSUCHIYA , Takehiko YAMAZAKI
Abstract: The present inventors have discovered that a peptide derived from HMGB1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB1 which is different from conventional uses.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.019 seconds)
